Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
ACCP 2023 | Bellevue, WA
Sep 10 - 12, 2023
Poster
The Effect of Food and the Proton Pump Inhibitor Esomeprazole on the Single-Dose Pharmacokinetics and Safety of ARV-766, a PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Healthy VolunteersMDS 2023 | Copenhagen, Denmark
Aug 27 - 31, 2023
Poster
Development of Potent, Orally Bioavailable, and Highly Selective LRRK2 PROTAC® Degrader Molecules as Potential Disease Modifying Therapeutics for Parkinson’s DiseaseMDS 2023 | Copenhagen, Denmark
Aug 27 - 31, 2023
Poster
LRRK2 PROTAC® Degrader Molecules Induce Robust Biomarker Responses in Preclinical In Vivo Pharmacology Studies Following Acute and Chronic Oral DosingASCO 2023 | Chicago, IL
Jun 2 - 6, 2023
Poster
TACTIVE-U: Phase 1b/2 Umbrella Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Combined with Other Anticancer Treatments in ER+ Advanced or Metastatic Breast CancerASCO 2023 | Chicago, IL
Jun 2 - 6, 2023
Poster
VERITAC-2: A Global, Randomized Phase 3 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast CancerESMO-BC 2023 | Berlin, Germany
May 11 - 13, 2023
Poster
TACTIVE-N: Open-Label, Randomized, Noncomparative Neoadjuvant Phase 2 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, or Anastrozole in Postmenopausal Women with ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Localized Breast CancerESMO-BC 2023 | Berlin, Germany
May 11 - 13, 2023
Poster
VERITAC Update: Phase 2 Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast CancerESMO-BC 2023 | Berlin, Germany
May 11 - 13, 2023
Poster
TACTIVE-E: Phase 1b Study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination with Everolimus in ER+/Human Epidermal Growth Factor Receptor 2 (HER2)-Advanced Breast CancerESMO-BC 2023 | Berlin, Germany
May 11 - 13, 2023